Association of Parvovirus B19 Serostatus with Elevated Serum Levels of Soluble Killer-cell Immunoglobulin-like Receptors (sKIR) in a Diverse Oncogenic Cohort: An Exploratory Cross-Sectional Study
The intricate relationship between viral persistence and human oncogenesis represents one of the most complex paradigms in contemporary immune-oncology, Where it is well-established that approximately 15% - 20% of global malignancies are attributable to viral etiologies, where pathogens do not merely act as transforming agents but also function as potent modulators of the Tumor Microenvironment (TME)¹ Beyond direct genomic instability, persistent viral infections often orchestrate a state of chronic inflammation and metabolic perturbation, ultimately facilitating immune subversion-a process by which the host’s defensive mechanisms are co-opted or suppressed to allow malignant progression².. Among the emerging viral candidates in this field is Parvovirus B19 (B19V), a small DNA virus traditionally associated with benign hematological conditions, However, emerging evidence suggests that B19V can establish lifelong persistence in various peripheral tissues and bone marrow, potentially serving as a chronic stimulus for immunological remodeling³. While the pathogenic role of B19V in autoimmune and inflammatory disorders is recognized, its specific influence on the specialized receptors of the innate immune system within a malignant context remains largely unexplored⁴. Central to the innate anti-tumor response are Natural Killer (NK) cells, whose cytolytic efficacy is strictly regulated by a diverse repertoire of surface molecules, most notably the Killer-cell Immunoglobulin-like Receptors (KIR)⁵. These receptors provide critical inhibitory or activating signals that maintain immunological homeostasis, However, the pathological upregulation of inhibitory KIRs can lead to immune exhaustion, where NK cells fail to recognize and eliminate transformed cells⁶.The hypothesis that viral pathogens like B19V may correlate with altered systemic levels of soluble KIR, potentially reflecting a state of immune dysregulation⁷. Despite the clinical significance of these pathways, there is a distinct lack of quantitative data correlating specific B19V serostatus (active IgM versus chronic IgG persistence) with systemic SKIR concentrations in cancer patients⁸. This study seeks to address this significant gap in the literature. By evaluating a substantial cohort of N=200 patients, we aim to delineate the relationship between B19V seropositivity and KIR-mediated signaling. Such an investigation is pivotal for "deciphering" the mechanisms of immune escape and may provide the foundation for novel therapeutic strategies aimed at restoring immune potency in virally associated malignancies.